CLINICAL TRIALS PROFILE FOR PATADAY TWICE DAILY RELIEF
✉ Email this page to a colleague
All Clinical Trials for Pataday Twice Daily Relief
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00534794 ↗ | Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2007-10-01 | The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis. |
| NCT01272089 ↗ | A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis | Completed | Alcon Research | Phase 4 | 2011-05-01 | The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study. |
| NCT01450176 ↗ | Comparing Patient Satisfaction With Pataday or Bepreve | Completed | McCabe Vision Center | N/A | 2011-09-01 | The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID). |
| NCT01470118 ↗ | A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis | Completed | Allergan | Phase 4 | 2011-10-01 | This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis. |
| NCT01732757 ↗ | A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis | Completed | Allergan | Phase 4 | 2012-11-01 | This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis. |
| NCT05265910 ↗ | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis | Recruiting | Andover Research Eye Institute | Phase 4 | 2021-12-14 | This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis. |
| NCT05314621 ↗ | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis | Recruiting | Andover Research Eye Institute | Phase 4 | 2021-12-31 | This is a single-center, randomized, double-masked, parallel study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pataday Twice Daily Relief
Condition Name
Clinical Trial Locations for Pataday Twice Daily Relief
Trials by Country
Clinical Trial Progress for Pataday Twice Daily Relief
Clinical Trial Phase
Clinical Trial Sponsors for Pataday Twice Daily Relief
Sponsor Name
